TPST-1495
Advanced solid tumors (e.g., endometrial cancer)
Phase 1/2Active
Key Facts
Indication
Advanced solid tumors (e.g., endometrial cancer)
Phase
Phase 1/2
Status
Active
Company
About Tempest Therapeutics
Tempest Therapeutics is pioneering the development of small molecule therapies that target the tumor microenvironment to overcome resistance and enhance anti-tumor immune responses. Its lead candidates are designed to inhibit immunosuppressive pathways, such as those driven by PPARα and prostaglandin receptors, with the goal of creating more effective treatments for advanced solid tumors. The company has advanced multiple programs into clinical development and is exploring strategic partnerships to maximize the potential of its pipeline. Tempest's approach aims to address significant unmet needs in oncology by combining its novel agents with established immunotherapies.
View full company profile